The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.

@article{Hsiou2001TheLM,
  title={The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.},
  author={Y. F. Hsiou and J. P. Ding and Kalyan Das and Arthur D. Clark and Paul L. Boyer and Paul J. Lewi and Paul A. J. Janssen and J P Kleim and Manfred Dr. R{\"o}sner and Stephen H. Hughes and Eddy Arnold},
  journal={Journal of molecular biology},
  year={2001},
  volume={309 2},
  pages={
          437-45
        }
}
Inhibitors of human immunodeficiency virus (HIV) reverse transcriptase (RT) are widely used in the treatment of HIV infection. Loviride (an alpha-APA derivative) and HBY 097 (a quinoxaline derivative) are two potent non-nucleoside RT inhibitors (NNRTIs) that have been used in human clinical trials. A major problem for existing anti-retroviral therapy is the emergence of drug-resistant mutants with reduced susceptibility to the inhibitors. Amino acid residue 103 in the p66 subunit of HIV-1 RT is… Expand
Mutation V111I in HIV-2 Reverse Transcriptase Increases the Fitness of the Nucleoside Analogue-Resistant K65R and Q151M Viruses
TLDR
Analysis of the polymerase, connection, and RNase H domains of RT in HIV-2 patients failing NRTI-containing therapies shows that V111I does not strongly affect drug susceptibility but increases the replication capacity of the K65R and Q151M viruses. Expand
The structure of FIV reverse transcriptase and its implications for non-nucleoside inhibitor resistance
TLDR
The first crystal structure of FIV RT is reported and, being the first structure of an RT from a non-primate lentivirus, it demonstrates that while the NNRTI binding pocket is conserved, minor subtleties at the entryway can render the Fiv RT pocket more restricted and unfavorable for effective NN RTI binding. Expand
Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse Transcriptase
TLDR
The combined use of structural biology and biochemical approaches has led to the discovery of novel mechanisms of drug resistance and has contributed to the design of new drugs with improved potency and ability to suppress multi-drug resistant strains. Expand
Looking for an Active Conformation of the Future HIV Type-1 Non-Nucleoside Reverse Transcriptase Inhibitors
TLDR
The characteristics of second-generation NNRTIs, including etravirine, rilpivirines, RDEA-806, UK-453061, BIRL 355 BS, IDX 899, MK-4965 and HBY 097 are reviewed. Expand
The search for potent, small molecule NNRTIs: A review.
TLDR
A chronological history of NNRTI development is presented, also highlighting the need for small molecules belonging to the NN RTI class for the management of AIDS. Expand
Mechanistic insights into the role of secondary mutations of HIV-1 reverse transcriptase in the acquisition of antiretroviral drug resistance
TLDR
The molecular mechanisms that facilitate the selection of mutations associated with TAMs during treatment with antiretroviral drugs are determined and predict that in the presence of NNRTIs, fitness differences between virus carrying the wild-type enzyme and the double-mutant N348I/T369I RT should be reduced. Expand
Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations.
TLDR
Recent knowledge on drug-resistance mutations within HIV reverse transcriptase (RT) is summarized, including mutations in the HIV-1 RT C-terminal region, including the connection subdomain and RNase H domain, whose clinical impacts are still controversial. Expand
Quantum Chemical Study of Molecular Recognition between Etravirine/Rilpivirine and the HIV-1 Reverse Transcriptase
Second generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) etravirine and rilpivirine are essential components in the highly active antiretroviral therapy for the treatment ofExpand
Crystal structures of clinically relevant Lys103Asn/Tyr181Cys double mutant HIV-1 reverse transcriptase in complexes with ATP and non-nucleoside inhibitor HBY 097.
Lys103Asn and Tyr181Cys are the two mutations frequently observed in patients exposed to various non-nucleoside reverse transcriptase inhibitor drugs (NNRTIs). Human immunodeficiency virus (HIV)Expand
Crystal structures of HIV-1 reverse transcriptases mutated at codons 100, 106 and 108 and mechanisms of resistance to non-nucleoside inhibitors.
TLDR
Six crystal structures of mutant RT-inhibitor complexes are determined and it is found that RT(Val108Ile) appears to act via an indirect mechanism which in this case is through alterations of the ring stacking interactions of the drug particularly with Tyr181. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 46 REFERENCES
Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase.
TLDR
The repositioning of efavirenz within the drug binding pocket of the mutant RT, together with conformational rearrangements in the protein, could represent a general mechanism whereby certain second-generation non-nucleoside inhibitors are able to reduce the effect of drug-resistance mutations on binding potency. Expand
Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.
TLDR
H BY 097 binds to the mutant RT in a manner similar to that seen in the wild-type RT/HBY 097 complex, although there are some repositioning and conformational alterations of the inhibitor, suggesting that inhibitor flexibility can help to minimize drug resistance. Expand
Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids.
  • S. Sarafianos, K. Das, +4 authors E. Arnold
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1999
TLDR
A model is developed that explains the ability of the 3TC-resistant mutant M184I to incorporate dNTPs but not the nucleotide analog 3TCTP and can also explain the 3 TC resistance of analogous hepatitis B polymerase mutants. Expand
The role of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection
TLDR
In vivo, various triple-drug combinations of NNRTIs with NRTIs and PIs and/or PIs have been shown to afford a durable anti-HIV activity, as reflected by both a decrease in plasma HIV-1 RNA levels and increased CD4 T-lymphocyte counts. Expand
Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors
TLDR
The structure of HIV-1 reverse transcriptase (RT) complexed with the nonnucleoside inhibitor TIBO R 86183 at 3.0 Å resolution is reported to provide a basis for understanding the nature of nonn DNA inhibitor binding, the structure of the binding site and the interactions between the bound inhibitors and surrounding amino acid residues. Expand
Resistance mutations selected in vivo under therapy with anti-HIV drug HBY 097 differ from resistance pattern selected in vitro.
TLDR
These findings highlight the crucial importance of IC50 determinations from cultured virus for determination of phenotypic resistance development during therapy and demonstrate that in vivo resistance development cannot be predicted from in vitro selection. Expand
The structure of HIV-1 reverse transcriptase complexed with 9-chloro-TIBO: lessons for inhibitor design.
TLDR
Although Cl-TIBO is chemically very different from other NNIs, it achieves remarkable spatial equivalence and shape complementarity with other NNs on binding to RT, and might enhance their binding and hence, potentially, their therapeutic efficacy. Expand
3'-Azido-3'-deoxythymidine drug resistance mutations in HIV-1 reverse transcriptase can induce long range conformational changes.
  • J. Ren, R. Esnouf, +7 authors D. Stammers
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
  • 1998
TLDR
The crystal structures of AZT- and ddI-resistant RTs have been determined and it is likely that long-range effects at the RT polymerase site mediated simply by the protein could represent a common mechanism for generating drug resistance in other systems. Expand
Structure of HIV-1 reverse transcriptase in a complex with the non-nucleoside inhibitor alpha-APA R 95845 at 2.8 A resolution.
TLDR
An understanding of the structure of the inhibitor-binding pocket, of the interactions between HIV-1 RT and alpha-APA, and of the locations of mutations that confer resistance to inhibitors provides a basis for structure-based design of chemotherapeutic agents for the treatment of AIDS. Expand
Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants.
Two analogues of the nonnucleoside inhibitor of HIV-1 RT, MKC-442 (emivirine), containing different C6 substituents have been designed to be less susceptible to the commonly found drug-resistanceExpand
...
1
2
3
4
5
...